Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture.

ABSTRACT: In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A investigation into 18 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The investigation identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that were able to inhibit SARS-CoV-2 infection. Confocal microscopy with over expressed S-protein demonstrated that Maraviroc reduced the extent of S-protein mediated cell fusion as observed by fewer multinucleate cells in the context of drug-treatment. Mathematical modeling of drug-depende

SUBMITTER: Risner KH 

PROVIDER: S-EPMC7430595 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature